Stockreport

Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Bicara Therapeutics Inc.  (BCAX) 
PDF Granted FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC Data from a Phase 1b expansion cohort ev [Read more]